Mevis Medical Solutions Stock EBITDA
| M3V Stock | 24.40 0.60 2.52% |
MeVis Medical Solutions fundamentals help investors to digest information that contributes to MeVis Medical's financial success or failures. It also enables traders to predict the movement of MeVis Stock. The fundamental analysis module provides a way to measure MeVis Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MeVis Medical stock.
MeVis |
MeVis Medical Solutions Company EBITDA Analysis
MeVis Medical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, MeVis Medical Solutions reported earnings before interest,tax, depreciation and amortization of 0.0. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as EBITDA (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
MeVis EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MeVis Medical's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MeVis Medical could also be used in its relative valuation, which is a method of valuing MeVis Medical by comparing valuation metrics of similar companies.MeVis Medical is currently under evaluation in ebitda category among its peers.
MeVis Fundamentals
| Current Valuation | 57.93 M | |||
| Price To Book | 3.43 X | |||
| Price To Sales | 3.67 X | |||
| Market Capitalization | 58.97 M | |||
| Total Asset | 31.2 M | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 31.2 M |
About MeVis Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MeVis Medical Solutions's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MeVis Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MeVis Medical Solutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MeVis Stock Analysis
When running MeVis Medical's price analysis, check to measure MeVis Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MeVis Medical is operating at the current time. Most of MeVis Medical's value examination focuses on studying past and present price action to predict the probability of MeVis Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MeVis Medical's price. Additionally, you may evaluate how the addition of MeVis Medical to your portfolios can decrease your overall portfolio volatility.